Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Protagonist Therapeutics's enterprise value is $9,134.8 Mil.
Protagonist Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $59.9 Mil. Therefore, Protagonist Therapeutics's EV-to-EBITDA for today is 152.54.
The historical rank and industry rank for Protagonist Therapeutics's EV-to-EBITDA or its related term are showing as below:
PTGX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.11 Med: -3.35 Max: 275.35
Current: 152.54
During the past 12 years, the highest EV-to-EBITDA of Protagonist Therapeutics was 275.35. The lowest was -57.11. And the median was -3.35.
PTGX's EV-to-EBITDA is ranked worse than 94.61% of 408
companies
in the Biotechnology industry
Industry Median: 14.13
vs PTGX: 152.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Protagonist Therapeutics's PE Ratio (TTM) for today is calculated as:
Protagonist Therapeutics's share price for today is $153.12.
Protagonist Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protagonist Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagonist Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's EV-to-EBITDA falls into.
Protagonist Therapeutics's current Enterprise Value is $9,134.8 Mil.
Protagonist Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $59.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics (PTGX) has a EV-to-EBITDA of 152.54 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Protagonist Therapeutics. According to the industry distribution chart, Protagonist Therapeutics ranks #386 out of 408 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Protagonist Therapeutics' EV-to-EBITDA too high?
Protagonist Therapeutics' current EV-to-EBITDA is 152.54. The Biotechnology industry median EV-to-EBITDA is 14.13. Protagonist Therapeutics' value of 152.54 is 979.5% above this industry median. Based on the distribution chart, Protagonist Therapeutics ranks #386 out of 408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' EV-to-EBITDA compare to CRNX and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #386 out of 408 companies for EV-to-EBITDA. This places Protagonist Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 14.13. Protagonist Therapeutics' value of 152.54 is 979.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.13, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagonist Therapeutics's current EV-to-EBITDA of 152.54 is 979.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Protagonist Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 14.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagonist Therapeutics's current EV-to-EBITDA is 152.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $90.10, compared to a current price of $153.12 — trading 69.9% above its estimated fair value. The current EV-to-EBITDA is 152.54 and 979.5% above the Biotechnology industry median of 14.13. Protagonist Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current EV-to-EBITDA is 152.54 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of $153.12 is trading 69.9% above its estimated GF Value™ of $90.10.
GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.
Key valuation signals for PTGX:
EV-to-EBITDA: 152.54
GF Value™: $90.10 vs. price of $153.12 (69.9% above fair value)
Industry Position: 979.5% above the Biotechnology median (#386 of 408)
No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
53GF Score
Get the complete analysis for PTGX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTGX has been successfully added to your 
